Patents Assigned to GW Pharma Limited
  • Publication number: 20100323038
    Abstract: The present invention relates to an improved mode of administration for cannabis and its natural and synthetic derivatives. A pharmaceutical composition suitable for sublingual aerosol or spray delivery of cannabis is provided. The formulation may be dispensed using a pump spray or the formulation may include a propellant, such as butane, 1,1,1,2-tetrafluoroethane (HFC-134a) or 1,1,1,2,3,3,3-heptafluoropropane (HFC-227). The term cannabis is used herein to refer to all physiologically active substances derived from the cannabis family of plants and synthetic cannabis analogues and derivatives, precursors, metabolites etc., or related substances having cannabis-like physiological effects.
    Type: Application
    Filed: August 10, 2010
    Publication date: December 23, 2010
    Applicant: GW Pharma Limited
    Inventor: Calvin Ross
  • Publication number: 20100317729
    Abstract: The present invention relates to a novel pharmaceutical formulation comprising a ratioed mix of: (i) one or more compounds that acts as an inverse agonist of the CB1 and/or CB2 receptor; and (ii) one or more compounds that acts as a neutral antagonist of the CB1 and/or CB2 receptor. Preferably both the inverse agonist of the CB1 and/or CB2 receptor and the neutral antagonist of the CB1 and/or CB2 receptor are cannabinoids. Preferably the cannabinoids are tetrahydrocannabidivarin (THCV) and cannabidiol (CBD).
    Type: Application
    Filed: July 4, 2008
    Publication date: December 16, 2010
    Applicant: GW Pharma Limited
    Inventors: Geoffrey Guy, Brian Anthony Whittle, Roger Pertwee
  • Publication number: 20100292345
    Abstract: The present invention relates to the use of the cannabinoid cannabigerol (CBG) in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from concurrent agonism of the CBi and the CB2 cannabinoid receptors. Such diseases or conditions to be treated are taken from the group: pain, neurodegenerative disease, ischemic disease, brain injury or damage, acquired brain injury, age related inflammatory or autoimmune disease, cachexia, nausea and vomiting, glaucoma, movement disorders, rheumatoid arthritis, asthma, allergy, psoriasis, Crohn's disease, systemic lupus erythematosus, diabetes, cancer, osteoporosis, renal ischemia and nephritis.
    Type: Application
    Filed: June 25, 2008
    Publication date: November 18, 2010
    Applicant: GW PHARMA LIMITED
    Inventor: Roger Pertwee
  • Publication number: 20100286098
    Abstract: The present invention relates to the use of a substantially pure tetrahydrocannabinol (THC) or a THC containing extract in which THC is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. A further embodiment of the invention relates to the use of a substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. Additionally the substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid are used in the manufacture of a medicament for use as an adjunct therapy in the treatment of an inflammatory bowel disease.
    Type: Application
    Filed: June 25, 2008
    Publication date: November 11, 2010
    Applicant: GW Pharma Limited
    Inventors: Philip Robson, Geoffrey Guy, Roger Pertwee, Joanna Jamontt
  • Publication number: 20100249223
    Abstract: The present invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of diseases or conditions that are alleviated by blockade of one or more types of TRP channel. Preferably the subset of TRP channel that is blockaded is the TRPA channel. More preferably the TRPA channel is the TRPA1 channel. Preferably the diseases or conditions to be prevented or treated include: neuropathic pain, inflammation or vasoconstriction. Alternatively the TRP channel that is blockaded is the TRPM channel. More preferably the TRPM channel is the TRPM8 channel. Preferably the diseases or conditions to be prevented or treated are cancer. More preferably the cancers to be treated include: cancer of the prostate, cancer of the breast, cancer of the colon, cancer of the lung or cancer of the skin. Alternatively the TRP channel that is blockaded is the TRPV channel. More preferably the TRPV channel is the TRPV1 channel.
    Type: Application
    Filed: April 17, 2008
    Publication date: September 30, 2010
    Applicant: GW Pharma Limited
    Inventors: Vincenzo Di Marzo, Luciano De Petrocellis, Aniello Schiano Moriello
  • Publication number: 20100239693
    Abstract: The invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration. In particular, the invention relates to use of one or more cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration, wherein the one or more cannabinoid-containing plant extracts comprise: i) a cannabinoid-containing fraction; and ii) a non-cannabinoid containing fraction.
    Type: Application
    Filed: January 17, 2007
    Publication date: September 23, 2010
    Applicant: GW Pharma Limited
    Inventors: Geoffrey Guy, Bettina Platt
  • Publication number: 20100196488
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Application
    Filed: February 12, 2010
    Publication date: August 5, 2010
    Applicant: GW Pharma Limited
    Inventor: Brian Whittle
  • Publication number: 20100168448
    Abstract: The invention relates to methods of preparing cannabinoids in substantially pure form starting from plant material. Also described are substantially pure preparations of various cannabinoids and cannabinoid acids, and also extracts enriched in cannabinoids and cannabinoid acids.
    Type: Application
    Filed: March 1, 2010
    Publication date: July 1, 2010
    Applicant: GW Pharma Limited
    Inventors: Ian Flockhart, Gary William Wheatley, Su Dring, Leslie Archer
  • Publication number: 20100119606
    Abstract: Processes for preparing extracts of natural products such as plant material, and for preparing purified extracts from crude extracts of natural products, by extraction with hot gas. Apparatus suitable for use in preparing extracts of natural products are also described.
    Type: Application
    Filed: November 13, 2009
    Publication date: May 13, 2010
    Applicant: GW Pharma Limited
    Inventors: Brian Whittle, Geoffrey Guy, David Downs, David W. Pate
  • Patent number: 7709536
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: May 4, 2010
    Assignee: GW Pharma Limited
    Inventor: Brian Whittle
  • Publication number: 20100035978
    Abstract: The present invention relates to the use of a combination of cannabinoids in the treatment of neuropathic pain, in particular peripheral neuropathic pain. A combination of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) may be used, wherein the ratio of CBD:THC by weight is between 10:1 and 1:10.
    Type: Application
    Filed: October 31, 2006
    Publication date: February 11, 2010
    Applicant: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Philip Robson
  • Publication number: 20100016418
    Abstract: The present invention relates to the use of cannabidiol (CBD) type compounds or derivative thereof and tetrahydro-cannabinol (THC) type compounds or derivative thereof in the manufacture of a medicament for the treatment of neuropathic pain. Preferably the ratio of the CBD type compounds or derivative thereof and THC type compounds or derivative thereof is between 18:1 and 30:1. More preferably the CBD type compounds or derivative thereof and THC type compounds or derivative thereof are in the form of plant extracts.
    Type: Application
    Filed: June 21, 2007
    Publication date: January 21, 2010
    Applicant: GW Pharma Limited
    Inventors: Geoffrey Guy, Barbara Costa
  • Publication number: 20090306221
    Abstract: The present invention relates to the use of one or more cannabinoids in the manufacture of medicaments for use in 0 the treatment of diseases and conditions benefiting from inverse agonism of the CB1 and/or the CB2 cannabinoid receptor. Preferably the cannabinoid is a cannabidiol (CBD) type compound or derivative thereof.
    Type: Application
    Filed: May 31, 2007
    Publication date: December 10, 2009
    Applicant: GW PHARMA LIMITED
    Inventors: Geoffrey Guy, Roger Pertwee, Adele Thomas
  • Patent number: 7622140
    Abstract: Processes for preparing extracts of natural products such as plant material, and for preparing purified extracts from crude extracts of natural products, by extraction with hot gas. Apparatus suitable for use in preparing extracts of natural products are also described.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: November 24, 2009
    Assignee: GW Pharma Limited
    Inventors: Brian Whittle, Geoffrey Guy, David Downs, David Pate
  • Patent number: 7537005
    Abstract: A dispensing system for medication comprising a dispenser (55, 56) into which the canister (60) of medication is placed. The dispenser has a locking mechanism for selectively preventing dispensing of the medication. The system receives input data from a user and has a control device remote from the dispenser to lock the dispenser until the input data is correctly entered. The dispenser may be configured by a cartridge (100) inserted into the dispenser in place of the canister (60). The dispenser also has means for determining its location and locking the device if the dispenser is not at or within a fixed location.
    Type: Grant
    Filed: February 24, 2003
    Date of Patent: May 26, 2009
    Assignee: GW Pharma Limited
    Inventor: Rajiv Bobby Dave
  • Publication number: 20090035396
    Abstract: The invention relates to a reference plant which has been selected to: a) not express a medicinally active compound or group of compounds; yet b) express, at least substantially qualitatively, most other non medicinally active compounds present in a therapeutically active comparator plant. The reference plant can be used to generate a reference extract with a reference chemical profile which resembles that of the comparator plant less the active compound or group of compounds and may thus be used as a placebo or to otherwise test the hypothesis that the active compound or compounds are responsible for an extracts perceived medicinal activity.
    Type: Application
    Filed: May 30, 2008
    Publication date: February 5, 2009
    Applicant: GW Pharma Limited
    Inventor: Etienne De Meijer
  • Publication number: 20080262099
    Abstract: The invention relates to the use of a cannabis plant extract or a cannabinoid as a pharmaceutically active agent in the inhibition of tumour cell migration.
    Type: Application
    Filed: September 30, 2005
    Publication date: October 23, 2008
    Applicant: GW Pharma Limited
    Inventors: Brian Whittle, Daniela Parolaro
  • Publication number: 20080167483
    Abstract: The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a BDS of given purity, for use in pharmaceutical formulations. In particular it relates to BDS comprising cannabinoids obtained by extraction from cannabis.
    Type: Application
    Filed: March 17, 2008
    Publication date: July 10, 2008
    Applicant: GW Pharma Limited
    Inventors: Brian A. Whittle, Colin A. Hill, Ian R. Flockhart, David V. Downs, Peter Gibson, Gary W. Wheatley
  • Publication number: 20080139667
    Abstract: The invention relates to the use of a combination of cannabinoids for the treatment of pain, inflammation and/or disease modification in arthritis. Preferably the cannabinoids are selected from cannabidiol (CBD) or cannabidivarin (CBDV) and delta-9-tetrahydrocannabinol (THC) or tetrahydrocannabinovarin (THCV). More preferably the cannabinoids are in a predefined ratio by weight of less than or equal to 19:1 of CBD or CBDV to THC or THCV.
    Type: Application
    Filed: June 7, 2005
    Publication date: June 12, 2008
    Applicant: GW Pharma Limited
    Inventors: Philip Robson, Geoffrey Guy
  • Publication number: 20080119544
    Abstract: The invention relates to the use of one or more cannabinolds in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from neutral antagonism of the CB, cannabinoid receptor. Preferably the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the diseases and conditions to be treated are taken from the group: obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimer's, bone disorders, bulimia, obesity associated with type n diabetes (non-insulin dependant diabetes) and in the treatment of drug, alcohol and nicotine abuse or dependency.
    Type: Application
    Filed: November 15, 2005
    Publication date: May 22, 2008
    Applicant: GW PHARMA LIMITED
    Inventors: Geoffrey William Guy, Roger Pertwee